Comparator choice scuppers BI/Lilly's Trajenta assessment in Germany
This article was originally published in Scrip
Executive Summary
Industry representatives are calling for the involvement of an independent comparator designator after IQWiG, Germany's Institute for Quality and Efficiency in Healthcare, was unable to conclude that Boehringer Ingelheim/Lilly's DPP4 inhibitor Trajenta (linagliptin) offered any additional benefit over comparators for glycaemic control in type 2 diabetes patients. The decision came after the firms chose Merck & Co's DPP-4 inhibitor Januvia (sitagliptin) as a comparator, rather than those prescribed by the G-BA, the committee in charge of reimbursement.